ROIV — Roivant Sciences Income Statement
0.000.00%
Last trade - 00:00- $21.55bn
- $18.02bn
- $8.26m
Annual income statement for Roivant Sciences, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2022 March 31st | R2023 March 31st | R2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 55.3 | 31.5 | 32.7 | 29.1 | 8.26 |
| Cost of Revenue | |||||
| Gross Profit | 46.3 | 28.5 | 31.1 | 28.1 | 6.97 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1,335 | 909 | -4,497 | 1,029 | 512 |
| Operating Profit | -1,280 | -877 | 4,530 | -1,000 | -504 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -924 | -885 | 4,568 | -682 | -265 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -924 | -889 | 4,546 | -730 | -398 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -845 | -1,009 | 4,349 | -172 | -300 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -845 | -1,009 | 4,349 | -172 | -300 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.783 | -0.988 | 1.44 | -0.853 | -1.16 |
| Dividends per Share |